NASDAQ
10.09.25 | 21:56
5,160 US-Dollar
-4,97 % -0,270
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Foghorn: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 05.08. | Foghorn Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
| 05.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 120 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
| 01.07. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Citizens JMP reiterates Foghorn stock with $9 target | 2 | Investing.com | ||
| 14.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 14.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.05. | Foghorn Therapeutics erweitert Vorstand mit Biotech-Veteranen | 2 | Investing.com Deutsch | ||
| 01.05. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 30.04. | Foghorn stock holds at $9 target, JMP affirms Market Outperform | 3 | Investing.com | ||
| 28.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | 1 | GlobeNewswire (USA) | ||
| 28.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | JMP starts Foghorn stock with $9 target, sees major opportunity | 1 | Investing.com | ||
| 15.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 25.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 116 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
| 20.03. | Foghorn Therapeutics scales down ATM stock offering to $100M | 1 | Seeking Alpha | ||
| 20.03. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,700 | -1,60 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,400 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ARCELLX | 72,71 | +0,93 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| NUVALENT | 78,50 | -0,29 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 86,45 | +0,06 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| 89BIO | 8,520 | -1,27 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,605 | 0,00 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| EVOTEC | 5,846 | +0,62 % | Evotec Prognose gekappt: Rettet der "Priority Reset"? | Evotec hat im Juli seine Umsatzprognose überraschend gesenkt und damit Anleger verunsichert. Trotz Kostensenkungen und der geplanten Veräußerung der Produktionsanlage in Toulouse bleibt das Vertrauen... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,360 | -6,74 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| TOURMALINE BIO | 47,590 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,830 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 38,590 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| AVIDITY BIOSCIENCES | 46,360 | 0,00 % | Avidity Biosciences kündigt Aktienemission im Wert von 500 Millionen US-Dollar an | ||
| TREVI THERAPEUTICS | 9,610 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,750 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen FOGHORN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,160 Euro und damit -4,97 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.